PRODUCT – Talk Bio

Eisai Adopts Elix Discovery Platform to Accelerate AI-Driven Drug Development

5 days ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, DAIIA, Drug Discovery, Eisai, Elix Discovery, federated learning, Initiative, Japan, joint research, pharmaceutical innovation

Eisai; Elix Discovery; AI drug discovery; federated learning; pharmaceutical innovation; joint research; Japan; DAIIA initiative

Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

2 weeks ago talkbio0Tagged Blood - brain barrier anatomy, Brain Delivery Module, dealmaking, Eledon, Iambic, Neuroscience discipline, Novartis, Revolution Medicines, Sernova, Sironax

Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon

Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Drug Discovery, Drug Industry, Iambic Therapeutics, milestone payments, Neoplasms, NeuralPLexer, propane, RAS-addicted cancers, Revolution Medicines

Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments

Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move

4 weeks ago talkbio0Tagged Bayer, bemdaneprocel, BlueRock Therapeutics, Cambridge research labs, Cell Therapy, Drug Industry, layoffs

BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

1 month ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot

1 month ago talkbio0Tagged Approved, Gilead, Guidelines, HIV Prevention, Lenacapavir, Long-acting injectable, PREP gene, twice-yearly injection, United States Food and Drug Administration, World Health Organization, Yeztugo

Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines

AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China pharma, Chronic disease, Collaboration, Dosage Forms, Drug Discovery, Drug Industry, GZMH gene, Immune System Diseases, milestone payments, oral therapies

AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry

FDA Launches AI Tool to Accelerate and Transform Drug Review Processes

1 month ago talkbio0Tagged AI tool, application assessment, Automation, drug review, Elsa, Generative AI, regulatory science, United States Food and Drug Administration

FDA; AI tool; drug review; rapid review; generative AI; regulatory science; Elsa; automation; application assessment

MIT’s Boltz-1 AI Model Rivals AlphaFold 3 in Biomolecular Structure Prediction

2 months ago talkbio0Tagged AlphaFold, Aortic Valve Insufficiency, Artificial Intelligence, biomolecular structure prediction, Boltz-1, Drug Discovery, MIT, open-source AI, protein folding

MIT; Boltz-1; AlphaFold 3; AI model; biomolecular structure prediction; drug discovery; protein folding; open-source AI

Ascletis’ Sagimet-Sourced Oral FASN Inhibitor Achieves All Endpoints in Pivotal Acne Study

2 months ago talkbio0Tagged Acne Vulgaris, Ascletis, Biosciences, Chinese study, clinical endpoints, Clinical Trials, Denifanstat, Inhibitor, Lesion, oral FASN, Phase 3, Sagimet

Ascletis; Sagimet Biosciences; denifanstat; oral FASN inhibitor; phase 3 clinical trial; acne vulgaris; clinical endpoints; lesion reduction; Chinese study